Ohr Pharmaceutical announces final topline data from OHR-102 phase II IMPACT study
Ohr Pharma announced topline results from the exploratory Phase II IMPACT study evaluating OHR-102 combination therapy for treatment of the wet-AMD. The positive effect on visual acuity in classic CNV was seen early in the course of treatment and continued to increase through the end of the study. March 27, 2015